.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Queensland Health
Fish and Richardson
UBS
McKinsey
Express Scripts
Healthtrust
Covington
Dow
US Department of Justice

Generated: September 20, 2017

DrugPatentWatch Database Preview

INTEGRILIN Drug Profile

« Back to Dashboard

What is the patent landscape for Integrilin, and what generic Integrilin alternatives are available?

Integrilin is a drug marketed by Schering and is included in one NDA.

The generic ingredient in INTEGRILIN is eptifibatide. There are thirteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the eptifibatide profile page.

Summary for Tradename: INTEGRILIN

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list27
Clinical Trials: see list10
Patent Applications: see list3,385
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:INTEGRILIN at DailyMed

Pharmacology for Tradename: INTEGRILIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 1998APRXYesYes► Subscribe► Subscribe► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-002May 18, 1998APRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: INTEGRILIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 1998► Subscribe► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 1998► Subscribe► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 1998► Subscribe► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 1998► Subscribe► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-002May 18, 1998► Subscribe► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-002May 18, 1998► Subscribe► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-002May 18, 1998► Subscribe► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 1998► Subscribe► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-002May 18, 1998► Subscribe► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-002May 18, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: INTEGRILIN

Drugname Dosage Strength RLD Submissiondate
eptifibatideInjection0.75 mg/mL, 100 mL vialIntegrilin6/5/2009
eptifibatideInjection2 mg/mL, 100 mL vialIntegrilin12/18/2008
eptifibatideInjection2 mg/mL, 10 mL vialIntegrilin9/30/2008
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
Cipla
Teva
Medtronic
Citi
Express Scripts
Queensland Health
Accenture
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot